254 related articles for article (PubMed ID: 24115912)
1. Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data.
Wieseler B; Wolfram N; McGauran N; Kerekes MF; Vervölgyi V; Kohlepp P; Kamphuis M; Grouven U
PLoS Med; 2013 Oct; 10(10):e1001526. PubMed ID: 24115912
[TBL] [Abstract][Full Text] [Related]
2. Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports.
Köhler M; Haag S; Biester K; Brockhaus AC; McGauran N; Grouven U; Kölsch H; Seay U; Hörn H; Moritz G; Staeck K; Wieseler B
BMJ; 2015 Feb; 350():h796. PubMed ID: 25722024
[TBL] [Abstract][Full Text] [Related]
3. Reporting of harms in oncological clinical study reports submitted to the European Medicines Agency compared to trial registries and publications-a methodological review.
Paludan-Müller AS; Créquit P; Boutron I
BMC Med; 2021 Apr; 19(1):88. PubMed ID: 33827569
[TBL] [Abstract][Full Text] [Related]
4. Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications.
Wieseler B; Kerekes MF; Vervoelgyi V; McGauran N; Kaiser T
BMJ; 2012 Jan; 344():d8141. PubMed ID: 22214759
[TBL] [Abstract][Full Text] [Related]
5. Opportunities for selective reporting of harms in randomized clinical trials: Selection criteria for non-systematic adverse events.
Mayo-Wilson E; Fusco N; Hong H; Li T; Canner JK; Dickersin K
Trials; 2019 Sep; 20(1):553. PubMed ID: 31488200
[TBL] [Abstract][Full Text] [Related]
6. Does access to clinical study reports from the European Medicines Agency reduce reporting biases? A systematic review and meta-analysis of randomized controlled trials on the effect of erythropoiesis-stimulating agents in cancer patients.
Rohner E; Grabik M; Tonia T; Jüni P; Pétavy F; Pignatti F; Bohlius J
PLoS One; 2017; 12(12):e0189309. PubMed ID: 29228059
[TBL] [Abstract][Full Text] [Related]
7. Reporting of harms outcomes: a comparison of journal publications with unpublished clinical study reports of orlistat trials.
Hodkinson A; Gamble C; Smith CT
Trials; 2016 Apr; 17(1):207. PubMed ID: 27103582
[TBL] [Abstract][Full Text] [Related]
8. Accessibility of clinical study reports supporting medicine approvals: a cross-sectional evaluation.
Hopkins AM; Modi ND; Rockhold FW; Hoffmann T; Menz BD; Veroniki AA; McKinnon RA; Rowland A; Swain SM; Ross JS; Sorich MJ
J Clin Epidemiol; 2024 Mar; 167():111263. PubMed ID: 38219810
[TBL] [Abstract][Full Text] [Related]
9. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
10. European Medicines Agency Policy 0070: an exploratory review of data utility in clinical study reports for academic research.
Ferran JM; Nevitt SJ
BMC Med Res Methodol; 2019 Nov; 19(1):204. PubMed ID: 31690260
[TBL] [Abstract][Full Text] [Related]
11. Access to regulatory data from the European Medicines Agency: the times they are a-changing.
Wieseler B; McGauran N; Kerekes MF; Kaiser T
Syst Rev; 2012 Oct; 1():50. PubMed ID: 23110993
[TBL] [Abstract][Full Text] [Related]
12. Comparison of conference abstracts and presentations with full-text articles in the health technology assessments of rapidly evolving technologies.
Dundar Y; Dodd S; Dickson R; Walley T; Haycox A; Williamson PR
Health Technol Assess; 2006 Feb; 10(5):iii-iv, ix-145. PubMed ID: 16487455
[TBL] [Abstract][Full Text] [Related]
13. The use of clinical study reports to enhance the quality of systematic reviews: a survey of systematic review authors.
Hodkinson A; Dietz KC; Lefebvre C; Golder S; Jones M; Doshi P; Heneghan C; Jefferson T; Boutron I; Stewart L
Syst Rev; 2018 Aug; 7(1):117. PubMed ID: 30089508
[TBL] [Abstract][Full Text] [Related]
14. Clinical study reports published by the European Medicines Agency 2016-2018: a cross-sectional analysis.
Byrne D; Prendergast C; Fahey T; Moriarty F
BMJ Open; 2023 May; 13(5):e068981. PubMed ID: 37188475
[TBL] [Abstract][Full Text] [Related]
15. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.
Oaklander AL; Lunn MP; Hughes RA; van Schaik IN; Frost C; Chalk CH
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010369. PubMed ID: 28084646
[TBL] [Abstract][Full Text] [Related]
16. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
17. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.
Miller JE; Wilenzick M; Ritcey N; Ross JS; Mello MM
BMJ Open; 2017 Dec; 7(12):e017917. PubMed ID: 29208616
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
